Floatz logo

2-(5-((3-ETHOXY-2-PYRIDYL)OXY)-3-PYRIDYL)-N-((3S,5S)-5-FLUORO-3-PIPERIDYL)PYRIMIDINE-5-CARBOXAMIDE

Non-Alcoholic Fatty Liver Disease

PfizerSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

140 Active assets in the Non-Alcoholic Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

2-(5-((3-ETHOXY-2-PYRIDYL)OXY)-3-PYRIDYL)-N-((3S,5S)-5-FLUORO-3-PIPERIDYL)PYRIMIDINE-5-CARBOXAMIDE is also rated in:

fibrotic liver diseaseDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →